Becton, Dickinson and Company (BDX)

Wall Street analysts covering Becton, Dickinson and Company currently rate the stock a Buy on average, with a mean 12-month price target of $192.00 — +4.6% versus the last price of $183.58. Targets reflect analyst opinion, not a guarantee.

24 members of Congress have disclosed trading BDX — 17 purchases and 24 sales worth an estimated $415,012. Most recent disclosure: May 21, 2026.

BDX's own executives and directors have made 0 open-market purchases ($0) and 7 sales ($1.2M) in the last 90 days, per SEC Form 4 filings. Most recent: Aug 11, 2026.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Company website ↗

• P/E ratio (31.3) — how many dollars you pay for each $1 of BDX's yearly profit. That's a fairly normal range.
• ROE (6.61%) — how efficiently the company turns shareholders' money into profit. This is a middling level.
• Profit margin (4.19%) — of every $1 in sales, this is what's left as profit after all costs.
• Dividend yield (2.32%) — the cash payout you'd earn per year as a % of the share price, on top of any price gains.